Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatment NOV03 (Perfluorohexyloctane)
VAUGHAN, ON and HEIDELBERG, Germany, July 7, 2022 — Bausch
bausch,
Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting
Five Presentations Will Highlight Findings from the XIPERE® Pivotal Phase
Bausch + Lomb Announces Brett Icahn and Gary Hu Have Been Appointed to its Board of Directors
VAUGHAN, ON, June 23, 2022 — Bausch + Lomb Corporation
Bausch + Lomb Announces the U.S. Launch of Revive™ Custom Soft Contact Lenses
“Using our proprietary technologies for spherical, multifocal, toric and multifocal
Bausch + Lomb Announces First-Quarter 2022 Results and Provides 2022 Guidance
First-Quarter 2022 Financial Results Revenues of $889 Million GAAP Net
Bausch + Lomb Announces Scientific Data on Latest Biotrue® Products to be Presented at American Optometric Association’s Optometry’s Meeting
Seven Presentations Will Include Unique Research on the New Biotrue®
Bausch + Lomb Announces the U.S. Launch of Biotrue® Hydration Plus Multi-Purpose Solution
“Building on our successful Biotrue® Multi-Purpose Solution brand, we developed Biotrue®
New Social Media Campaign From Bausch + Lomb Aims to Raise Awareness that Cataracts Don’t Wait
Campaign Includes Educational Social Media Posts to Broaden Patient Awareness
Bausch + Lomb Announces Participation at the RBC Capital Markets Global Healthcare Conference
VAUGHAN, ON, May 13, 2022 — Bausch + Lomb Corporation,
Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions
LAVAL, QC and VAUGHAN, ON, May 10, 2022 — Bausch
BAUSCH + LOMB CORPORATION LAUNCHES AS A PUBLICLY TRADED COMPANY
Bausch + Lomb Begins Trading under “BLCO” on NYSE and
Bausch + Lomb valued at $6.5 billion after stock ticks up in NYSE debut
By Niket Nishant (Reuters) -Bausch + Lomb was valued at
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
NOV03 Met Primary Endpoints for Signs and Symptoms of Dry
Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting
13 Poster Presentations Include Results from Second Pivotal Phase 3
Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation
LAVAL, QC and VAUGHAN, ON, April 28, 2022 — Bausch
Bausch + Lomb Corporation Announces Launch of IPO and Roadshow
LAVAL, QC and VAUGHAN, ON, April 28, 2022 — Bausch
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
NOV03 Met Both Primary Endpoints for Signs and Symptoms of
Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
VAUGHAN, ON and LAVAL, QC and TRENTON, N.J., April 21, 2022
Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health
The Term Loan Facility is expected to mature in 2027.
Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting
“Bausch + Lomb is committed to supporting continuous scientific exchange
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
“XIPERE® is the first and only therapy available in the